Compare ARMP & SAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARMP | SAR |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 383.7M | 372.7M |
| IPO Year | 1996 | N/A |
| Metric | ARMP | SAR |
|---|---|---|
| Price | $11.31 | $22.36 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | $15.00 | ★ $23.75 |
| AVG Volume (30 Days) | 49.2K | ★ 100.4K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 14.45% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.39 |
| P/E Ratio | ★ N/A | $9.44 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.17 | $20.78 |
| 52 Week High | $14.98 | $25.64 |
| Indicator | ARMP | SAR |
|---|---|---|
| Relative Strength Index (RSI) | 48.53 | 47.92 |
| Support Level | $5.14 | $21.40 |
| Resistance Level | $12.11 | $22.82 |
| Average True Range (ATR) | 1.40 | 0.49 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 30.02 | 35.59 |
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.